Navigation Links
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Date:8/21/2008

neys, leading to inflammation, the formation of disfiguring nodules (tophi), intermittent attacks of severe pain (acute flares), and kidney damage (nephropathy). While gout is a treatable condition, there are limited treatment options and a number of adverse effects are associated with current therapies. No new therapies have been approved by the FDA for the treatment of hyperuricemia associated with gout in the past 40 years

About RDEA594

RDEA594, our lead product candidate for the treatment of gout, is a major metabolite of RDEA806, our lead non-nucleoside reverse transcriptase inhibitor (NNRTI) in clinical development for the treatment of HIV. RDEA594 does not have antiviral activity and is believed to be responsible for the uric acid-lowering effects observed following administration of RDEA806 to over 100 subjects in Phase 1 and Phase 2 clinical trials. In Phase 1 studies of RDEA806 in normal healthy volunteers, increased urinary excretion of uric acid was observed in the first 24 hours after dosing, with statistically significant, exposure-dependent, decreases in serum uric acid of 35% to 50% observed during multiple dosing out to 14 days.

About RDEA806

RDEA806 is a novel NNRTI for the potential treatment of HIV infection. Based on preclinical and clinical studies to date, we believe that RDEA806 may have important competitive advantages compared to currently available NNRTIs. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)) and other currently available NNRTIs; a high genetic barrier to resistance; limited pharmacokinetic interactions with other drugs; no reproductive toxicity based on animal studies; and the potential to be readily co-formulated in a single pill with other HIV antiviral drugs, such as Truvada(R) (emtricitabine and tenofovir) from Gilead Sciences, Inc, which is important for patient compliance.

A
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Hologic, Inc. (NASDAQ: HOLX ), ... and Chief Executive Officer, will preside over the NASDAQ ... first day of Breast Cancer Awareness Month. In his ... on the important benefits of Hologic,s 3D Mammography technology, ... clinically superior to traditional mammography. This is ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, ... an overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
(Date:10/1/2014)... 01, 2014 Two bicyclists began a ... across the country in an effort to raise funds ... The cyclists, a father-daughter team, plan to bike ... Blaine, Washington and finishing in Key West Florida. ... The Warriors®, a national nonprofit organization that assists post-9/11 ...
(Date:10/1/2014)... UP4 Probiotics will be donating a portion ... National Network to End Domestic Violence ( http://www.nnedv.org ) ... through nationwide polling that took place during August and ... , “We are proud to have been chosen by ... of UP4 Women’s Probiotics during the month of October,” ...
(Date:10/1/2014)... 2014 After a run of successful ... emerging filmmaker Jacqui Blue is continuing her mission to ... truth about natural birth. The documentary has received a ... world and has been an effective medium for starting ... highlighted in the film provide a wealth of information ...
(Date:10/1/2014)... Looking for holiday gift ideas? Éminence Organic ... gift giving easy this holiday season. Starting October 1st 2014, ... solve all shopping dilemmas. Choose from two luxury skin care ... the delicate eye area or to deliver whole body beauty. ... Rescue Duo Gift Set are formulated to suit all skin ...
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 The annual ... levels again in 2015, says a new forecast by ... most recent consumer price index (CPI) data through August, TSCL ... “That would make the sixth consecutive year of record low ... the COLA first became automatic in 1975,” he notes. , ...
Breaking Medicine News(10 mins):Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 4Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 3Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... Research (AADR) has announced Irwin D. Mandel, AADR past president ... of the inaugural 2010 AADR Distinguished Mentoring Award. This award ... in Washington, DC, March 3, 2010. Mandel began ... up his part-time private practice in 1968 to devote himself ...
... could lead to new treatments, study suggests , FRIDAY, Feb. ... for cystic fibrosis, U.S. researchers have identified a defective signaling ... disease. , Cystic fibrosis causes thick, sticky mucus to build ... of the most common potentially lethal genetic diseases in children ...
... ... ... ... ...
... ... ... the release of the 2010 U.S. Ambulatory EHR Study, a strategic analysis of the U.S. ... (HITECH) component of the American Recovery and Reinvestment (ARRA) Act. ,As recently presented at the ...
... they closely matched the real personalities of the profile ... the notion that Internet users favor idealized virtual identities, ... networking sites such as Facebook create profiles that stick ... networks may be more interested in fostering real communication ...
... ... ... ... ...
Cached Medicine News:Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 3Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 5Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 6Health News:CapSite Announces Release of the 2010 U.S. Ambulatory EHR Study 2Health News:Facebook Profiles Don't Stretch the Truth 2Health News:Facebook Profiles Don't Stretch the Truth 3Health News:Facebook Profiles Don't Stretch the Truth 4Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 2Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 3Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 4Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 5Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 6Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 7Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 8Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 9Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 10Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 11Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 12Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 13Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 14Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 15Health News:Nuvo Research announces 2009 fourth quarter and year-end financial results 16
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
... is indicated for use in the thoracolumbar spine ... or excised for the treatment of tumors, to ... neural tissues, and to restore the height of ... also indicated for treating fractures of the thoracic ...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
Medicine Products: